In 1947, Dr. Sidney Farber's pioneering research developed modern chemotherapy for children with leukemia. Dana-Farber Cancer Institute has been a worldwide medical research leader ever since. Today, we are applying our pioneering research tradition
to developing novel approaches towards understanding and treating COVID-19.
Dana-Farber scientists are developing groundbreaking strategies to bar the COVID-19 virus from entering cells — thus preventing infection and averting transmission of the virus. Supported by the National Institutes of Health (NIH) and other funding organizations,
we are collaborating with fellow scientists worldwide to map an understanding of how the virus interacts with its host human proteins.
Our researchers are also at the forefront of developing antibody therapy for COVID-19 — utilizing a Dana-Farber-developed collection of 27 billion human antibodies against viruses, bacteria, and other bodily invaders. Dana-Farber's prior experience in
developing treatments for SARS, MERS, and other viral-borne illnesses gives us a deep level of expertise for attacking this new virus.